February 6, 2014
Kyowa Hakko Kirin said on February 4 that it has launched a PIII clinical study of its investigational c-Met inhibitor ARQ 197 (tivantinib) for hepatocellular cancer in Japan. The randomized, double-blind placebo-controlled study will recruit 160 patients with c-Met diagnostic-high...read more